Taking on H5N1 | GenomeWeb

Taking on H5N1

NIH announced that a vaccine for H5N1 avian flu designed by scientists at the National Institute of Allergy and Infectious Diseases has entered clinical trials. The DNA-based vaccine is the first to start human trials, according to NIH. If all goes well with this vaccine, it could help pave the way for development of other DNA-based, rather than virus-based, vaccines.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.